Angioimmunoblastic T-cell lymphoma (AITL) is an age-related malignant lymphoma, characterized by immune system-dysregulated symptoms. Recent sequencing studies have clarified the recurrent mutations in ras homology family member A (RHOA) and in genes encoding epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2), DNA methyl transferase 3 alpha (DNMT3A) and isocitrate dehydrogenase 2, mitochondrial (IDH2), as well as those related to the T-cell receptor signaling pathway in AITL.
individuals may be tightly linked to the age-related premalignant mutations in AITL. (Note: See the Section, "1.9.") AITL patients display generalized lymphadenopathy, a characteristic symptom of malignant lymphomas. Furthermore, the symptoms suggestive of immunologic hyperactivation are also present in AITL: fever, rash, Coombs test-positive hemolytic anemia and polyarthritis. 3 and macrophages, invade AITL tissues. 3 Moreover, the blood vessels are markedly increased and often surrounded by AITL tumor cells. In addition, follicular dendritic cells (FDC) are also prominently present near the tumor cells and blood vessels. 3 As mentioned above, AITL tumor cells resemble cytokine-producing and chemokine-producing TFH cells. 4 Cytokines and chemokines released from TFH-like tumor cells may recruit immune cells, blood vessels and FDC into AITL tissues, and activate them to further produce cytokines and chemokines. This positive circuit of cytokines and chemokines may exacerbate the trafficking of these cells into AITL tissues. For instance, the CXCL13 and its receptor CXCR5 network is thought to promote recruitment of B cells and FDC as well as tumor cells into AITL tissues. 3 Vascular endothelial growth factor (VEGF), a cytokine that promotes angiogenesis, is expressed in both tumor and vascular endothelial cells. 5 Cytokine-producing helper T17 (Th17) cells as well as CD8-positive T cells are also enriched in AITL tissues. 6 Mast cells in AITL tissues function as producers of VEGF, to recruit endothelial cells, 7 and of interleukin-6 (IL-6), to proliferate Th17 cells. 8 Although the cytokine and chemokine circuit originating from TFH-like tumor cells may account for the massive infiltration of immune cells into AITL tissues, novel genetic evidence indicated that tumor-infiltrating cells may not be entirely attributable to the reactive process. 9 The infiltrating B cells in AITL tissues had gene mutations distinct from those found in tumor cells. 9 The genetic events in tumor-infiltrating cells may synergize with the cytokine-and chemokine-mediated reactions to produce the pathologic features of AITL.
(Note: See the Section below, "1.10.")
1.4 | Ras homology family member A, epigenetic regulators, and T-cell signaling molecules are the main players in the genetic abnormalities of angioimmunoblastic T-cell lymphoma
Recent genetic studies identified recurrent mutations in ras homolog family member A (RHOA) (50%-70%) [10] [11] [12] and in genes encoding the epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2) (47%-83%), 10, 13 DNA methyltransferase 3 alpha (DNMT3A) (20%-30%) 10, 11, 14 and isocitrate dehydrogenase 2, mitochondrial (IDH2) (20%-45%), 10, 15 as well as the components of the TCR signaling pathways, phospholipase C gamma 1 (PLC c) (14%), 16 CD28 (9%-11%), 16, 17 FYN protooncogene, Src family tyrosine kinase (FYN) (3%-4%) 11, 16 and vav guanine nucleotide exchange factor 1 (VAV1) (5%) 16 in AITL (Table 1) .
Almost all the RHOA mutations found in AITL were p.G17V (G17V RHOA mutations). [10] [11] [12] G17V RHOA mutations were commonly observed in the other nodal T-cell lymphomas with TFH phenotype:
57%-62% of nodal PTCL with TFH phenotype 10, 14 and 60% of FTCL, 14 while they were quite rare in other diseases. In contrast, TET2 and DNMT3A mutations were found in a broad range of hematologic malignancies, 18 and even in healthy elderly individuals. 19, 20 The mutations involving components of the TCR signaling pathways were commonly observed in nodal PTCL with TFH phenotype, 16 although CD28 mutations were specific to AITL. 17 Notably, the AITL genome exhibited a specific combination of these mutations: the RHOA-mutated samples also had TET2 mutations, while a part of the RHOA and TET2-mutated samples had IDH2 mutations. 10 These combinations may have a synergistic effect on oncogenesis.
1.5 | Diagnostic impact of G17V ras homology family member A mutations
As mentioned above, G17V RHOA mutations were commonly identified in nodal T-cell lymphomas with the TFH phenotype, 10,14 although they were also observed in a few cases of adult T-cell leukemia/lymphoma 21 which can be distinguished by its integration of human T-lymphotropic virus (HTLV)-1. Therefore, G17V RHOA mutations serve as a genetic indicator to detect nodal T-cell lymphomas with the TFH phenotype. The tumor ratio is sometimes low because of the prominent reactive cells, which makes it difficult to detect G17V RHOA mutations by direct sequencing. It is reported that the allele-specific PCR (AS-PCR) assay is an easy-to-use method to detect G17V RHOA mutations. 22 The positive and negative concordance rates between AS-PCR and amplicon-based deep sequencing were as high as 95%.
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RHOA mutations were also detectable in cell-free DNA, enabling their application in noninvasive diagnostic testing of AITL. bound active state. 25 The 17th glycine of RHOA is located at a position essential for binding to GTP. 10 In a Rhotekin pull-down assay to detect GTP-bound RHOA, the G17V RHOA mutant was not bound to GTP, [10] [11] [12] indicating that the G17V RHOA mutant does not mediate classical RHOA signaling. Curiously, the p.K18N mutant existing in a few AITL samples had higher GTP-binding capacity. 16 Therefore, the oncogenic roles of the G17V RHOA mutant in AITL development may not be due to the disruption of classical RHOA signaling.
Rather, the existence of mutations at a single amino acid strongly suggests that the G17V mutant acquires a specific oncogenic role.
Recently it was reported that the G17V mutant activated TCR pathway through direct binding to VAV1, an essential mediator of the TCR pathway. 26 Together with the frequent mutations in TCR pathway, aberrant activation of TCR pathway by the G17V RHOA mutant may be a clue for AITL development. (See the Section, "1.8.")
Other RHOA mutations are reported in diffuse-type gastric carcinoma, 27 Burkitt lymphoma 28 and ATLL. 21 The most frequent RHOA mutations in gastric carcinoma and Burkitt lymphoma were the p.Y42C and p.R5Q mutations, 27, 28 while the p.C16R mutations were the most frequent in ATLL. 21 Whether these various RHOA mutations share common downstream molecules essential for oncogenesis remains to be elucidated.
| Mutations in epigenetic regulators
TET2 encodes a methylcytosine, dioxygenase, to convert methylation cytosine (mC) to hydroxymethylcytosine (hmC), formylcytosine (fC) and carboxylcytosine (CaC). 29 These modified cytosines function as intermediates of the passive or active demethylating process, and as epigenetic marks. 29 Nonsense and frameshift mutations were distributed throughout the entire TET2 protein, while missense mutations almost always existed at the C-terminal catalytic domain in AITL, as in myeloid malignancies. 10, 13 have also been described. FYN mutations found in the SH2 domain and C terminus were activating mutations, presumably through the disruption of the intramolecular inhibitory interaction between the SH2 domain and the C terminus. 11 PLCc mutations were found in several functional motifs, including the PI-PLC, SH2, SH3 and C2
domain. PLCc mutations were also shown to be activating mutations, 16 although the biologic consequence of these mutations has yet to be clarified. VAV1 mutations were found at several hotspots, 16 although the oncogenic mechanisms of these mutations remain unclear. In addition, the C-terminal portion of VAV1, participating in intramolecular inhibition, was recurrently deleted by 2 distinct mechanisms: an alternative splicing mechanism resulting from in-flame deletion of the N-terminal site of the CSH3 domain 40 and formation of fusion genes with several distinct partners. 40, 41 Although the genetic evidence suggests that activation of TCR signaling by gene mutations may play a role in the symptoms and progression of AITL, it has not been exactly proven by in vivo experiments. Cyclosporin A, a calcineurin inhibitor that blocks TCR signaling, is widely used for the treatment of immune system-mediated diseases. 42 Cyclosporin A as a single reagent 43 or with other immunosuppressive reagents 44 was shown to effectively ameliorate the progression and symptoms of AITL. The effectiveness of cyclosporine A supports the hypothesis that activation of TCR signaling may actually contribute to AITL progression and that it can be a candidate pathway in targeted therapies. 46 Whether the multiple diseases in these cases actually had common ancestors remains to be elucidated.
Finally, somatic mutations were also detected even in healthy individuals. 19, 20 Mutation frequencies were reportedly increased with age: by 5% for those in their 60s, by 10% to 15% for those in their 70s, and by 10% to 25% for those in their 80s. 19, 20 Somatic mutations were also detected in 95% of individuals aged 50-60 years when the detection sensitivity was set at 0.0003 variant allele frequencies (VAF). 47 The most frequently mutated genes in the healthy individuals were DNMT3A, TET2 and ASXL1. 19, 20 Although these mutations were first found in hematologic malignancies, they may be defined as age-related mutations. The status of having somatic mutations without any evidence of hematologic diseases is called clonal hematopoiesis of indeterminate potential (CHIP). 48 CHIP was related to a high incidence of blood cancers and inferior overall survival. 19, 20 The presence of premalignant mutations in AITL patients suggests that CHIP may precede AITL in most cases. However, the actual incidence rate of AITL caused by CHIP has not been determined.
Indeed, because of its rarity, it would be tough to determine the incidence rate.
TET2 and DNMT3A mutations themselves in premalignant cells may not be sufficient to induce AITL development. Multiple TET2 mutations were frequently observed in AITL tissues, 10 while TET2 mutations were heterozygous in CHIP as well as in myeloid malignancies. When the distribution of TET2 mutations were examined in 19 AITL/PTCL samples using laser microdissection followed by targeted sequencing, 10 samples had 2 distinct TET2 mutations, while 6 had one TET2 mutation. 9 Although both mutations were determined as premalignant mutations in 5 of the samples, the 5 samples had 1 mutation as a premalignant mutation and the other as a tumor-specific mutation. 9 These observations suggest that the profound defect in TET2 function may skew premalignant cells into tumor cells. In addition, RHOA and IDH2 mutations were detected in tumor cells, 9 suggesting that acquisition of these mutations together with preexisting TET2 and DNMTA mutations leads to AITL development.
| Clonal evolution in tumor-infiltrating B cells
As mentioned above, the massive infiltration of immune cells into AITL tissues is partly due to the cytokine and chemokine storm, beginning from the cytokine and chemokine production from tumor cells and being amplified by the tumor-infiltrating inflammatory cells.
At the same time, it is well known that rearrangement of immunoglobulin (Ig) genes in addition to that of TCR genes is found in 0% to 40% of AITL samples, 3 (Figures 1 and 2 ). 9 Remarkably, B-cell specific mutations were also identified. 9 In particular, all 3 NOTCH1 mutations exhibited B-cell-specific distribution (Figures 1 and 2 ). These observations suggest that B cells residing in AITL tissues may have undergone clonal selection.
1.11 | Angioimmunoblastic T-cell lymphoma mouse model mimicking the human angioimmunoblastic Tcell lymphoma genome
The impact of genetic events on AITL development can be examined using mouse models. As mentioned above, loss-of-function TET2 mutations were highly frequent in AITL. 10 It was reported that TFH cells
were gradually increased and finally T-cell lymphomas with the TFH phenotype developed at long latencies in Tet2 gene-trap mice. 55 The lymphoma cells exhibited increased methylation at the transcriptional start site (TSS) regions, gene bodies and CpG islands, and decreased hydroxymethylation at the TSS regions. 55 In particular, the negative regulatory region of BCL6 encoding a fate-determinant of TFH cells was highly methylated in lymphoma cells. 55 Decitabine treatment results in demethylation of the loci, accompanying downregulation of Bcl6 expression. 55 Furthermore, human PTCL samples also had hypermethylation of the corresponding loci, especially when they had TET2
mutations. 56 The impaired TET2 function may induce BCL6 upregulation, resulting in the skewed differentiation toward TFH cells in both   AITL1  AITL2  AITL3  AITL4  AITL5  AITL6  AITL7  AITL8  AITL9  AITL10  AITL11  AITL12  AITL13  PTCL1  PTCL2  PTCL3 humans and mice. The synergistic effect of TET2 and DNMT3A mutations on AITL development was proven using mice transplanted with Tet2-null hematopoietic stem/progenitor cells expressing genes transduced with R882H DNMT3A mutant cDNA. 33 The synergistic effect of TET2 and G17V RHOA mutations, the most frequent combinations in human AITL, was also shown by mice transplanted with Tet2-null T cells expressing genes transduced with G17V RHOA mutant cDNA. 
